|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Renne SL, Sarcognato S, Sacchi D, Guido M,
Roncalli M, Terracciano L and Di Tommaso L: Hepatocellular
carcinoma: A clinical and pathological overview. Pathologica.
113:203–217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sangro B, Sarobe P, Hervas-Stubbs S and
Melero I: Advances in immunotherapy for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 18:525–543. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kudo M: Combination cancer immunotherapy
in hepatocellular carcinoma. Liver Cancer. 7:20–27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Formenti SC, Rudqvist NP, Golden E, Cooper
B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari
de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces
responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dendy MS, Ludwig JM, Stein SM and Kim HS:
Locoregional therapy, immunotherapy and the combination in
hepatocellular carcinoma: Future directions. Liver Cancer.
8:326–340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu S, Chao Y, Hu Y, Zhang Y, Hong W, Chen
Y, Chen R, Zeng Z and Du S: Radiotherapy enhances efficacy of PD-1
inhibitors in advanced hepatocellular carcinoma: A
propensity-matched real-world study. Chin Med J (Engl).
137:1332–1342. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl
TR, Francica BJ, Velarde E, Deweese TL and Drake CG: Stereotactic
radiation therapy augments antigen-specific PD-1-mediated antitumor
immune responses via cross-presentation of tumor antigen. Cancer
Immunol Res. 3:345–355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ngwa W, Irabor OC, Schoenfeld JD, Hesser
J, Demaria S and Formenti SC: Using immunotherapy to boost the
abscopal effect. Nat Rev Cancer. 18:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Zhang H, Xin Zhang and Liu Y:
Abscopal effect: From a rare phenomenon to a new frontier in cancer
therapy. Biomark Res. 12:982024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Formenti SC and Demaria S: Combining
radiotherapy and cancer immunotherapy: A paradigm shift. J Natl
Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Correction. Consensus guidelines for the
definition, detection and interpretation of immunogenic cell death.
J Immunother Cancer. 8:e000337corr12020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JY, Kim DH, Kim JH, Lee D, Jeon HB,
Kwon SJ, Kim SM, Yoo YJ, Lee EH, Choi SJ, et al: Soluble
intracellular adhesion molecule-1 secreted by human umbilical cord
blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell
Death Differ. 19:680–691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demaria S, Coleman CN and Formenti SC:
Radiotherapy: Changing the game in immunotherapy. Trends Cancer.
2:286–294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bonaventura P, Shekarian T, Alcazer V,
Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C and
Depil S: Cold Tumors: A therapeutic challenge for immunotherapy.
Front Immunol. 10:1682019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Friedman D, Baird JR, Young KH, Cottam B,
Crittenden MR, Friedman S, Gough MJ and Newell P: Programmed cell
death-1 blockade enhances response to stereotactic radiation in an
orthotopic murine model of hepatocellular carcinoma. Hepatol Res.
47:702–714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rimassa L, Finn RS and Sangro B:
Combination immunotherapy for hepatocellular carcinoma. J Hepatol.
79:506–515. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tojjari A, Yu J and Saeed A: Immunotherapy
and radiation therapy combinatorial approaches in hepatocellular
carcinoma. Cancers (Basel). 16:10582024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dawood ZS, Brown ZJ, Alaimo L, Lima HA,
Shaikh C, Katayama ES, Munir MM, Moazzam Z, Endo Y, Woldesenbet S
and Pawlik TM: Comparison of tumor response and outcomes of
patients with hepatocellular carcinoma after multimodal treatment
including immune checkpoint inhibitors-a systematic review and
meta-analysis. HPB (Oxford). 26:618–629. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee YH, Tai D, Yip C, Choo SP and Chew V:
Combinational immunotherapy for hepatocellular carcinoma:
Radiotherapy, immune checkpoint blockade and beyond. Front Immunol.
11:5687592020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bicak M, Cimen Bozkus C and Bhardwaj N:
Checkpoint therapy in cancer treatment: Progress, challenges, and
future directions. J Clin Invest. 134:e1848462024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harding JJ, Nandakumar S, Armenia J,
Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika
I, et al: Prospective genotyping of hepatocellular carcinoma:
Clinical implications of next-generation sequencing for matching
patients to targeted and immune therapies. Clin Cancer Res.
25:2116–2126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Zhou J, Wu M, Hu C, Yang J, Li D,
Wu P, Chen Y, Chen P, Lin S, et al: Low-dose total body irradiation
can enhance systemic immune related response induced by
hypo-fractionated radiation. Front Immunol. 10:3172019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klug F, Prakash H, Huber PE, Seibel T,
Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et
al: Low-dose irradiation programs macrophage differentiation to an
iNOS(+)/M1 phenotype that orchestrates effective T cell
immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li S, Li K, Wang K, Yu H, Wang X, Shi M,
Liang Z, Yang Z, Hu Y, Li Y, et al: Low-dose radiotherapy combined
with dual PD-L1 and VEGFA blockade elicits antitumor response in
hepatocellular carcinoma mediated by activated intratumoral CD8(+)
exhausted-like T cells. Nat Commun. 14:77092023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mizumoto M, Okumura T, Hashimoto T, Fukuda
K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A,
et al: Proton beam therapy for hepatocellular carcinoma: A
comparison of three treatment protocols. Int J Radiat Oncol Biol
Phys. 81:1039–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wahl DR, Stenmark MH, Tao Y, Pollom EL,
Caoili EM, Lawrence TS, Schipper MJ and Feng M: Outcomes after
stereotactic body radiotherapy or radiofrequency ablation for
hepatocellular carcinoma. J Clin Oncol. 34:452–459. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Juloori A, Katipally RR, Lemons JM, Singh
AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, et
al: Phase 1 Randomized trial of stereotactic body radiation therapy
followed by nivolumab plus ipilimumab or nivolumab alone in
advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol
Biol Phys. 115:202–213. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Q, Ji X, Sun J, Zhang A, Jia J, Zhang
T, Li W and Duan X: Stereotactic body radiotherapy combined with
lenvatinib with or without PD-1 inhibitors as initial treatment for
unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol
Phys. 120:1363–1376. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li JX, Su TS, Gong WF, Zhong JH, Yan LY,
Zhang J, Li LQ, He ML, Zhang RJ, Du YQ, et al: Combining
stereotactic body radiotherapy with camrelizumab for unresectable
hepatocellular carcinoma: A single-arm trial. Hepatol Int.
16:1179–1187. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiang CL, Chan ACY, Chiu KWH and Kong FS:
Combined stereotactic body radiotherapy and checkpoint inhibition
in unresectable hepatocellular carcinoma: A potential synergistic
treatment strategy. Front Oncol. 9:11572019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu Q, Xie J, Mei W and Zeng C: Methylated
circulating tumor DNA in hepatocellular carcinoma: A comprehensive
analysis of biomarker potential and clinical implications. Cancer
Treat Rev. 128:1027632024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu RH, Wei W, Krawczyk M, Wang W, Luo H,
Flagg K, Yi S, Shi W, Quan Q, Li K, et al: Circulating tumour DNA
methylation markers for diagnosis and prognosis of hepatocellular
carcinoma. Nat Mater. 16:1155–1161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Howell J, Atkinson SR, Pinato DJ, Knapp S,
Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Buttner R, et
al: Identification of mutations in circulating cell-free tumour DNA
as a biomarker in hepatocellular carcinoma. Eur J Cancer.
116:56–66. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Angeli-Pahim I, Chambers A, Duarte S, Soma
D, Beduschi T, Sahin I, Hughes S and Zarrinpar A: Methylated ctDNA
quantification: Noninvasive approach to monitoring hepatocellular
carcinoma burden. J Am Coll Surg. 238:770–778. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fridman WH, Zitvogel L, Sautes-Fridman C
and Kroemer G: The immune contexture in cancer prognosis and
treatment. Nat Rev Clin Oncol. 14:717–734. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun R, Limkin EJ, Vakalopoulou M, Dercle
L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S,
et al: A radiomics approach to assess tumour-infiltrating CD8 cells
and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging
biomarker, retrospective multicohort study. Lancet Oncol.
19:1180–1191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Han X, Guo Y, Ye H, Chen Z, Hu Q, Wei X,
Liu Z and Liang C: Development of a machine learning-based
radiomics signature for estimating breast cancer TME phenotypes and
predicting anti-PD-1/PD-L1 immunotherapy response. Breast Cancer
Res. 26:182024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim J and Jung Y: Radiation-induced liver
disease: Current understanding and future perspectives. Exp Mol
Med. 49:e3592017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lawrence TS, Robertson JM, Anscher MS,
Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting
from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Emami B, Lyman J, Brown A, Coia L, Goitein
M, Munzenrider JE, Shank B, Solin LJ and Wesson M: Tolerance of
normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol
Phys. 21:109–122. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rammohan N, Randall JW and Yadav P:
History of technological advancements towards MR-Linac: The future
of image-guided radiotherapy. J Clin Med. 11:47302022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Khaledi N, Khan R and Gräfe JL: Historical
progress of stereotactic radiation surgery. J Med Phys. 48:312–327.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Khoo VS, Dearnaley DP, Finnigan DJ,
Padhani A, Tanner SF and Leach MO: Magnetic resonance imaging
(MRI): considerations and applications in radiotherapy treatment
planning. Radiother Oncol. 42:1–15. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lawrence TS, Ten Haken RK, Kessler ML,
Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews
JC, Ensminger WD, et al: The use of 3-D dose volume analysis to
predict radiation hepatitis. Int J Radiat Oncol Biol Phys.
23:781–788. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Timmerman RD, Kavanagh BD, Cho LC, Papiez
L and Xing L: Stereotactic body radiation therapy in multiple organ
sites. J Clin Oncol. 25:947–952. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang L, Ke Q, Huang Q, Shao L, Chen J and
Wu J: Stereotactic body radiotherapy versus radiofrequency ablation
for hepatocellular carcinoma: A systematic review and
meta-analysis. Int J Hyperthermia. 37:1313–1321. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu DH, Liu L and Chen LH: Therapeutic
effects and prognostic factors in three-dimensional conformal
radiotherapy combined with transcatheter arterial chemoembolization
for hepatocellular carcinoma. World J Gastroenterol. 10:2184–2189.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Blomgren H, Lax I, Naslund I and Svanstrom
R: Stereotactic high dose fraction radiation therapy of
extracranial tumors using an accelerator. Clinical experience of
the first thirty-one patients. Acta Oncol. 34:861–870. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hall JT, Moon AM, Young M, Tan X,
Darawsheh R, Danquah F, Tepper JE and Yanagihara TK: Biochemical
safety of SBRT to multiple intrahepatic lesions for hepatocellular
carcinoma. J Hepatocell Carcinoma. 11:443–454. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hardy-Abeloos C, Lazarev S, Ru M, Kim E,
Fischman A, Moshier E, Rosenzweig K and Buckstein M: Safety and
efficacy of liver stereotactic body radiation therapy for
hepatocellular carcinoma after segmental transarterial
Radioembolization. Int J Radiat Oncol Biol Phys. 105:968–976. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Park SH, Kim JC and Kang MK: Technical
advances in external radiotherapy for hepatocellular carcinoma.
World J Gastroenterol. 22:7311–7321. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Koay EJ, Owen D and Das P:
Radiation-induced liver disease and modern radiotherapy. Semin
Radiat Oncol. 28:321–331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cárdenes HR, Price TR, Perkins SM,
Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K,
Deluca J and Johnstone PA: Phase I feasibility trial of
stereotactic body radiation therapy for primary hepatocellular
carcinoma. Clin Transl Oncol. 12:218–225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Culleton S, Jiang H, Haddad CR, Kim J,
Brierley J, Brade A, Ringash J and Dawson LA: Outcomes following
definitive stereotactic body radiotherapy for patients with
Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol.
111:412–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Apisarnthanarax S, Barry A, Cao M, Czito
B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer
J, et al: External beam radiation therapy for primary liver
cancers: An ASTRO clinical practice guideline. Pract Radiat Oncol.
12:28–51. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt
T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, et al:
American association of physicists in medicine task Group 263:
Standardizing nomenclatures in radiation oncology. Int J Radiat
Oncol Biol Phys. 100:1057–1066. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schaub SK, Hartvigson PE, Lock MI, Hoyer
M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS and
Apisarnthanarax S: Stereotactic body radiation therapy for
hepatocellular carcinoma: Current trends and controversies. Technol
Cancer Res Treat. 17:15330338187902172018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rim CH and Seong J: Application of
radiotherapy for hepatocellular carcinoma in current clinical
practice guidelines. Radiat Oncol J. 34:160–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Crane CH and Koay EJ: Solutions that
enable ablative radiotherapy for large liver tumors: Fractionated
dose painting, simultaneous integrated protection, motion
management, and computed tomography image guidance. Cancer.
122:1974–1986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Deng GL, Zeng S and Shen H: Chemotherapy
and target therapy for hepatocellular carcinoma: New advances and
challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huang A, Yang XR, Chung WY, Dennison AR
and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal
Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lee SU and Kim TH: Current evidence and
the potential role of proton beam therapy for hepatocellular
carcinoma. Clin Mol Hepatol. 29:958–968. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wennerberg E, Lhuillier C, Vanpouille-Box
C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC and
Demaria S: Barriers to radiation-induced in situ tumor vaccination.
Front Immunol. 8:2292017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lu Z, Polan DF, Wei L, Aryal MP,
Fitzpatrick K, Wang C, Cuneo KC, Evans JR, Roseland ME, Gemmete JJ,
et al: PET/CT-based absorbed dose maps in (90)Y selective internal
radiation therapy correlate with spatial changes in liver function
derived from dynamic MRI. J Nucl Med. 65:1224–1230. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li
JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al: Sequential
transarterial chemoembolisation and stereotactic body radiotherapy
followed by immunotherapy as conversion therapy for patients with
locally advanced, unresectable hepatocellular carcinoma
(START-FIT): A single-arm, phase 2 trial. Lancet Gastroenterol
Hepatol. 8:169–178. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Finn RS, Ryoo BY, Merle P, Kudo M,
Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et
al: Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: A Randomized,
double-blind, phase III trial. J Clin Oncol. 38:193–202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kudo M, Matilla A, Santoro A, Melero I,
Gracian AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R,
El-Rayes B, et al: CheckMate 040 cohort 5: A phase I/II study of
nivolumab in patients with advanced hepatocellular carcinoma and
Child-Pugh B cirrhosis. J Hepatol. 75:600–609. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB,
Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al:
Efficacy and safety of nivolumab plus ipilimumab in patients with
advanced hepatocellular carcinoma previously treated with
sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol.
6:e2045642020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sangro B, Melero I, Wadhawan S, Finn RS,
Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, et al:
Association of inflammatory biomarkers with clinical outcomes in
nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol. 73:1460–1469. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk
O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G,
Bassaganyas L, Akers N, et al: Identification of an immune-specific
class of hepatocellular carcinoma, based on molecular features.
Gastroenterology. 153:812–826. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Cheng AL, Hsu C, Chan SL, Choo SP and Kudo
M: Challenges of combination therapy with immune checkpoint
inhibitors for hepatocellular carcinoma. J Hepatol. 72:307–319.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ning C, Zhang X, Wang Y, Yang X, Yang X,
Chao J, Xun Z, Xue J, Wang Y, Sun H, et al: Radiation therapy with
combination therapy of immune checkpoint inhibitors and
antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat
Oncol Biol Phys. 118:1461–1471. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Song Y, Fu Y, Xie Q, Zhu B, Wang J and
Zhang B: Anti-angiogenic agents in combination with immune
checkpoint inhibitors: A promising strategy for cancer treatment.
Front Immunol. 11:19562020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vafaei S, Zekiy AO, Khanamir RA, Zaman BA,
Ghayourvahdat A, Azimizonuzi H and Zamani M: Combination therapy
with immune checkpoint inhibitors (ICIs); a new frontier. Cancer
Cell Int. 22:22022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux
M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J and Lencioni R:
IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab
versus sorafenib in patients with barcelona clinic liver cancer
stage B unresectable hepatocellular carcinoma: An exploratory
analysis of the phase III study. Liver Cancer. 12:238–250. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ali S, Arshad M, Summer M, Zulfiqar M,
Noor S, Nazakat L and Javed MA: Recent developments on checkpoint
inhibitors, CAR T cells, and beyond for T cell-based
immunotherapeutic strategies against cancer. J Oncol Pharm Pract.
Mar 28–2025.(Epub ahead of print). View Article : Google Scholar
|
|
91
|
Osaki M and Sakaguchi S: Soluble CTLA-4
regulates immune homeostasis and promotes resolution of
inflammation by suppressing type 1 but allowing type 2 immunity.
Immunity. 58:889–908.e13. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sangro B, Chan SL, Kelley RK, Lau G, Kudo
M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK,
et al: Four-year overall survival update from the phase III
HIMALAYA study of tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. Ann Oncol. 35:448–457. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Saygin I, Cakir E, Kazaz SN, Guvercin AR,
Eyupoglu I and Ustaoglu MM: Investigation of the status of immune
checkpoint molecules (PD-L1 and PD-1) in meningiomas by
immunohistochemistry. Turk J Med Sci. 54:735–743. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang Z, Liu X, Chen D and Yu J:
Radiotherapy combined with immunotherapy: The dawn of cancer
treatment. Signal Transduct Target Ther. 7:2582022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chang Y, Chang M, Bao X and Dong C:
Advancements in adoptive CAR immune cell immunotherapy
synergistically combined with multimodal approaches for tumor
treatment. Bioact Mater. 42:379–403. 2024.PubMed/NCBI
|
|
97
|
Garg AD, Nowis D, Golab J, Vandenabeele P,
Krysko DV and Agostinis P: Immunogenic cell death, DAMPs and
anticancer therapeutics: An emerging amalgamation. Biochim Biophys
Acta. 1805:53–71. 2010.PubMed/NCBI
|
|
98
|
Krysko DV, Garg AD, Kaczmarek A, Krysko O,
Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in
cancer therapy. Nat Rev Cancer. 12:860–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Garg AD, Galluzzi L, Apetoh L, Baert T,
Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R,
Cirone M, et al: Molecular and translational classifications of
DAMPs in immunogenic cell death. Front Immunol. 6:5882015.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Galluzzi L, Buque A, Kepp O, Zitvogel L
and Kroemer G: Immunogenic cell death in cancer and infectious
disease. Nat Rev Immunol. 17:97–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Apetoh L, Ghiringhelli F, Tesniere A,
Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E,
Saulnier P, et al: Toll-like receptor 4-dependent contribution of
the immune system to anticancer chemotherapy and radiotherapy. Nat
Med. 13:1050–1059. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ghiringhelli F, Apetoh L, Tesniere A,
Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G,
Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic
cells induces IL-1beta-dependent adaptive immunity against tumors.
Nat Med. 15:1170–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Krysko DV, Agostinis P, Krysko O, Garg AD,
Bachert C, Lambrecht BN and Vandenabeele P: Emerging role of
damage-associated molecular patterns derived from mitochondria in
inflammation. Trends Immunol. 32:157–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Palm NW and Medzhitov R: Pattern
recognition receptors and control of adaptive immunity. Immunol
Rev. 227:221–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rock KL and Kono H: The inflammatory
response to cell death. Annu Rev Pathol. 3:99–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zitvogel L, Kepp O and Kroemer G: Decoding
cell death signals in inflammation and immunity. Cell. 140:798–804.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Oura K, Morishita A, Tani J and Masaki T:
Tumor immune microenvironment and immunosuppressive therapy in
hepatocellular carcinoma: A review. Int J Mol Sci. 22:58012021.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chen R, Du J, Zhu H and Ling Q: The role
of cGAS-STING signalling in liver diseases. JHEP Rep. 3:1003242021.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ren B, Luo S, Xu F, Zou G, Xu G, He J,
Huang Y, Zhu H and Li Y: The expression of DAMP proteins HSP70 and
cancer-testis antigen SPAG9 in peripheral blood of patients with
HCC and lung cancer. Cell Stress Chaperones. 22:237–244. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Amiri M, Molavi O, Sabetkam S, Jafari S
and Montazersaheb S: Stimulators of immunogenic cell death for
cancer therapy: Focusing on natural compounds. Cancer Cell Int.
23:2002023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Singh V, Kaur R, Kumari P, Pasricha C and
Singh R: ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and
cardiovascular disorders. Clin Chim Acta. 548:1174872023.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K,
Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling
inhibition for cancer immunotherapy: Mechanism, combinations, and
clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Pandey P, Khan F, Qari HA, Upadhyay TK,
Alkhateeb AF and Oves M: Revolutionization in cancer therapeutics
via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4.
Pharmaceuticals (Basel). 15:3352022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yu S, Jiang S, Zhou Y, Zhu Z and Yang X:
Impact of radiation on exosomes in regulating tumor immune
microenvironment. Adv Radiat Oncol. 9:1015492024. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Pedros C, Canonigo-Balancio AJ, Kong KF
and Altman A: Requirement of Treg-intrinsic CTLA4/PKCη signaling
pathway for suppressing tumor immunity. JCI Insight. 2:e956922017.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Binder DC, Fu YX and Weichselbaum RR:
Radiotherapy and immune checkpoint blockade: Potential interactions
and future directions. Trends Mol Med. 21:463–465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Liu Y, Dong Y, Kong L, Shi F, Zhu H and Yu
J: Abscopal effect of radiotherapy combined with immune checkpoint
inhibitors. J Hematol Oncol. 11:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bae SH, Chun SJ, Chung JH, Kim E, Kang JK,
Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T, et al:
Stereotactic body radiation therapy for hepatocellular carcinoma:
meta-analysis and international stereotactic radiosurgery society
practice guidelines. Int J Radiat Oncol Biol Phys. 118:337–351.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Schaue D and McBride WH: Opportunities and
challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol.
12:527–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM,
Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, et al: Effects of
stereotactic body radiation therapy plus PD-1 inhibitors for
patients with transarterial chemoembolization refractory. Front
Oncol. 12:8396052022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhai J, Gu X, Liu Y, Hu Y, Jiang Y and
Zhang Z: Chemotherapeutic and targeted drugs-induced immunogenic
cell death in cancer models and antitumor therapy: An update
review. Front Pharmacol. 14:11529342023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kroemer G, Galassi C, Zitvogel L and
Galluzzi L: Immunogenic cell stress and death. Nat Immunol.
23:487–500. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Manda K, Glasow A, Paape D and Hildebrandt
G: Effects of ionizing radiation on the immune system with special
emphasis on the interaction of dendritic and T cells. Front Oncol.
2:1022012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kim KJ, Lee HW and Seong J: Combination
therapy with anti-T-cell immunoglobulin and mucin-domain containing
molecule 3 and radiation improves antitumor efficacy in murine
hepatocellular carcinoma. J Gastroenterol Hepatol. 36:1357–1365.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chen H, Zhao L, Fu K, Lin Q, Wen X,
Jacobson O, Sun L, Wu H, Zhang X, Guo Z, et al: Integrin
α(v)β(3)-targeted radionuclide therapy combined with immune
checkpoint blockade immunotherapy synergistically enhances
anti-tumor efficacy. Theranostics. 9:7948–7960. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Shao Y, Han S, Hou Z, Yang C and Zhao Y:
Tumor-associated macrophages within the immunological milieu: An
emerging focal point for therapeutic intervention. Heliyon.
10:e368392024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Tai WM, Yong WP, Lim C, Low LS, Tham CK,
Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, et al: A phase Ib study
of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib
in advanced hepatocellular carcinoma (HCC). Ann Oncol.
27:2210–2215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Kim BH, Park HC, Kim TH, Koh YH, Hong JY,
Cho Y, Sinn DH, Park B and Park JW: Concurrent nivolumab and
external beam radiation therapy for hepatocellular carcinoma with
macrovascular invasion: A phase II study. JHEP Rep. 6:1009912023.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Buckstein M, Kim E, Ozbek U, Tabrizian P,
Gunasekaran G, Facciuto M, Rosenzweig K, Llovet JM and Schwartz M:
Combination transarterial chemoembolization and stereotactic body
radiation therapy for unresectable single large hepatocellular
carcinoma: Results from a prospective phase 2 trial. Int J Radiat
Oncol Biol Phys. 114:221–230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chiang CL, Chiu KW, Lee FA, Kong FS and
Chan AC: Combined stereotactic body radiotherapy and immunotherapy
versus transarterial chemoembolization in locally advanced
hepatocellular carcinoma: A propensity score matching analysis.
Front Oncol. 11:7988322021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Chiang CL, Lee FAS, Chan KSK, Lee VWY,
Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, et al:
Survival outcome analysis of stereotactic body radiotherapy and
immunotherapy (SBRT-IO) versus SBRT-alone in unresectable
hepatocellular carcinoma. Liver Cancer. 13:265–276. 2023.PubMed/NCBI
|
|
134
|
Ning C, Jia J, Zhang X, Sun J, Wang Y, Xue
J, Zhang L, Hou X, Yang X, Sang X, et al: Efficacy and safety of
subsequent radiotherapy in patients with advanced-stage
hepatocellular carcinoma treated with immune checkpoint inhibitors.
Hepatobiliary Surg Nutr. 12:882–897. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Filatenkov A, Baker J, Mueller AM, Kenkel
J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S,
et al: Ablative tumor radiation can change the tumor immune cell
microenvironment to induce durable complete remissions. Clin Cancer
Res. 21:3727–3739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Vanpouille-Box C, Alard A, Aryankalayil
MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN,
Formenti SC and Demaria S: DNA exonuclease Trex1 regulates
radiotherapy-induced tumour immunogenicity. Nat Commun.
8:156182017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Robbins JR, Schmid RK, Hammad AY, Gamblin
TC and Erickson BA: Stereotactic body radiation therapy for
hepatocellular carcinoma: Practice patterns, dose selection and
factors impacting survival. Cancer Med. 8:928–938. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Herrera FG, Ronet C, Ochoa de Olza M,
Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A,
Benedetti F, Genolet R, et al: Low-Dose radiotherapy reverses tumor
immune desertification and resistance to immunotherapy. Cancer
Discov. 12:108–133. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Petragallo R, Bardach N, Ramirez E and
Lamb JM: Barriers and facilitators to clinical implementation of
radiotherapy treatment planning automation: A survey study of
medical dosimetrists. J Appl Clin Med Phys. 23:e135682022.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Han-Oh S, Hill C, Kang-Hsin Wang K, Ding
K, Wright JL, Alcorn S, Meyer J, Herman J and Narang A: Geometric
reproducibility of fiducial markers and efficacy of a
patient-specific margin design using deep inspiration breath hold
for stereotactic body radiation therapy for pancreatic cancer. Adv
Radiat Oncol. 6:1006552021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Marks LB, Bentzen SM, Deasy JO, Kong FM,
Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV,
Timmerman RD, et al: Radiation dose-volume effects in the lung. Int
J Radiat Oncol Biol Phys. 76 (3 Suppl):S70–S76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Higgins K, Hu C, Ross H, Jabbour S, Kozono
D, Owonikoko T, Dib E, Brownstein J, Kuzma C and Kotecha R:
Concurrent chemoradiation±atezolizumab (atezo) in limited-stage
small cell lung cancer (LS-SCLC): results of NRG Oncology/Alliance
LU005. Int J Radiat Oncol Biol Phys. 120:S22024. View Article : Google Scholar
|
|
143
|
Young KH, Baird JR, Savage T, Cottam B,
Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS,
et al: Optimizing timing of immunotherapy improves control of
tumors by hypofractionated radiation therapy. PLoS One.
11:e01571642016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Gunderson AJ and Young KH: Exploring
optimal sequencing of radiation and immunotherapy combinations. Adv
Radiat Oncol. 3:494–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Aliru ML, Schoenhals JE, Venkatesulu BP,
Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M,
Aziz KE, Welsh JW and Krishnan S: Radiation therapy and
immunotherapy: What is the optimal timing or sequencing?
Immunotherapy. 10:299–316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Theelen WSME, Peulen HMU, Lalezari F, van
der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I,
Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after
stereotactic body radiotherapy vs pembrolizumab alone on tumor
response in patients with advanced non-small cell lung cancer:
Results of the PEMBRO-RT phase 2 Randomized clinical trial. JAMA
Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Theelen WSME, Chen D, Verma V, Hobbs BP,
Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot
PM, et al: Pembrolizumab with or without radiotherapy for
metastatic non-small-cell lung cancer: a pooled analysis of two
randomised trials. Erratum in: Lancet Respir Med. 9:e292021.
|
|
148
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Haanen J, Obeid M, Spain L, Carbonnel F,
Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, et al:
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
33:1217–1238. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Thompson JA, Schneider BJ, Brahmer J,
Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi
S, Davies M, et al: Management of immunotherapy-related toxicities,
version 1.2022, NCCN clinical practice guidelines in oncology. J
Natl Compr Canc Netw. 20:387–405. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gumus M, Mazieres J, Hermes B, Cay Senler F, Csoszi T, Fulop A, et
al: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell
Lung Cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Sangro B, Chan SL, Meyer T, Reig M,
El-Khoueiry A and Galle PR: Diagnosis and management of toxicities
of immune checkpoint inhibitors in hepatocellular carcinoma. J
Hepatol. 72:320–341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Jácome AA, Castro ACG, Vasconcelos JPS,
Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF,
Gil RA, et al: Efficacy and safety associated with immune
checkpoint inhibitors in unresectable hepatocellular carcinoma: A
meta-analysis. JAMA Netw Open. 4:e21361282021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Li G, Zhao Y, Li K, Yang S, Xiang C, Song
J, Yang Y, Li G and Dong J: Effectiveness and safety of the PD-1
inhibitor lenvatinib plus radiotherapy in patients with HCC with
main PVTT: Real-world data from a tertiary centre. J Hepatocell
Carcinoma. 10:2037–2048. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Huang Y, Zhang Y, Zhang M, Zhao K, Feng L,
Guan J, Dong R, Liu J, Tian D, Liu M, et al: Combined immunotherapy
for hepatocellular carcinoma: How to maximize immune checkpoint
blockade synergic anti-tumor effect. Crit Rev Oncol Hematol.
189:1040702023. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Yang Y, Xiong L, Li M, Jiang P, Wang J and
Li C: Advances in radiotherapy and immunity in hepatocellular
carcinoma. J Transl Med. 21:5262023. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z,
Huang X, Wu Y, Li T and Guo W: Pembrolizumab plus lenvatinib with
or without hepatic arterial infusion chemotherapy in selected
populations of patients with treatment-naive unresectable
hepatocellular carcinoma exhibiting PD-L1 staining: A multicenter
retrospective study. BMC Cancer. 21:11262021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Garin E, Tselikas L, Guiu B, Chalaye J,
Edeline J, de Baere T, Assenat E, Tacher V, Robert C,
Terroir-Cassou-Mounat M, et al: Personalised versus standard
dosimetry approach of selective internal radiation therapy in
patients with locally advanced hepatocellular carcinoma
(DOSISPHERE-01): A randomised, multicentre, open-label phase 2
trial. Lancet Gastroenterol Hepatol. 6:17–29. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Lewandowski RJ and Salem R:
Radioembolisation with personalised dosimetry: Improving outcomes
for patients with advanced hepatocellular carcinoma. Lancet
Gastroenterol Hepatol. 6:2–3. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Zhu R, Wang X, Sun F, Zhu L and Guo W:
Exploring the role of DNA methylation located in
cuproptosis-related genes: Implications for prognosis and immune
landscape in hepatocellular carcinoma. Front Biosci (Landmark Ed).
29:1232024. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Zhu J, Tang B, Lv X, Meng M, Weng Q, Zhang
N, Li J, Fan K, Zheng L, Fang S, et al: Identifying
apoptosis-related transcriptomic aberrations and revealing clinical
relevance as diagnostic and prognostic biomarker in hepatocellular
carcinoma. Front Oncol. 10:5191802021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Nebhan CA and Johnson DB: Predictive
biomarkers of response to immune checkpoint inhibitors in melanoma.
Expert Rev Anticancer Ther. 20:137–145. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Xu H, Liang XL, Liu XG and Chen NP: The
landscape of PD-L1 expression and somatic mutations in
hepatocellular carcinoma. J Gastrointest Oncol. 12:1132–1140. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Parikh ND, Singal AG, Hutton DW and Tapper
EB: Cost-effectiveness of hepatocellular carcinoma surveillance: An
assessment of benefits and harms. Am J Gastroenterol.
115:1642–1649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Lani L, Stefanini B and Trevisani F:
Surveillance for hepatocellular carcinoma in patients with
successfully treated viral disease of the liver: A systematic
review. Liver Cancer. 13:376–388. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zafar SY, Alexander SC, Weinfurt KP,
Schulman KA and Abernethy AP: Decision making and quality of life
in the treatment of cancer: A review. Support Care Cancer.
17:117–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Hamann J, Kissling W and Mendel R: Does it
matter whether physicians' recommendations are given early or late
in the decision-making process? An experimental study among
patients with schizophrenia. BMJ Open. 6:e0112822016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Nahm WJ, Bhatt A and Wu J: Role of
radiotherapy and its contribution to immunotherapy in
hepatocellular carcinoma. Chin Clin Oncol. 12:412023. View Article : Google Scholar : PubMed/NCBI
|
